ARV7

Prostate cancer is the second most common cancer in the world for men. One of the treatment options for prostate cancer is the use
of hormonal treatment. However, recently developed therapies for Castration-Resistant Prostate Cancer (CRPC) by hormone has not been effective for 20 to 40 percent of CRPC patients.

One of the postulated mechanisms for this resistance is the development or presence of androgen receptor splice variants. ARV7 aims to find out the prevalence and incidence of the AR-V7 splice variant in an Asian population of patients with CRPC and to study how different treatments impact the patient outcomes in this group of patients.

The study is co-funded by global pharmaceutical company Sanofi and National Medical Research Council (NMRC). There are eight participating sites within key hospitals in five countries: Singapore, Malaysia, Hong Kong, Thailand and Japan. SCRI supports the project management and prepares sites in Singapore for study initiation.

SCRI provides support for the study by allocating a project manager as the main point of contact for sites and internal teams, a clinical research associate to assist sites with approval processes and a pharmacovigilance team for serious adverse event (SAE) reporting.

The data manager from SCRI works closely with the Principal Investigator (PI) and biostatisticians to custom-build a database management system, Oracle Clinical, in addition to providing data analysis and query management services.

ARV7 is unique: It would provide data for comparisons with recent publications and study the effect of the AR-V7 variant on the Asian population. It also showcases the successful partnership between a private global pharmaceutical company, Sanofi, with our public institutions, National Cancer Centre Singapore (NCCS) and SCRI.